GW PHARMA DOUBLES CANNABIS DRUG TRIALS

Simon Bowers- Guardian, The (UK)

Fri, 12 Apr 2002

GW Pharmaceuticals, which holds the sole UK licence to develop cannabis-based medicines, yesterday doubled the number of its clinical trials to discover the medical benefits of the drug.

Four new trials of the firm's under the tongue spray will be carried out on patients with spinal cord injuries, multiple sclerosis and nerve path damage. GW hopes they will help prove the drugs can ease pain and help sleep.

This brings the number of patients involved in seven GW clinical trials to about 600. Executive chairman Geoffrey Guy said he hoped to have a further three clinical trials under way within the next two months.

snip-

Read Complete Article Here